

Washington State Pharmacy and Therapeutics Committee

Drug Utilization Review Board

Date: February 21, 2018

Time: 9 a.m. to 2:30 p.m.

Port of Seattle "International A" Conference Room

Seattle-Tacoma International Airport

17801 International Blvd., Seattle, WA 98158

9 a.m.	Welcome & Introductions New member introductions Drug Utilization Review (DUR) Board Convenes	Dale Sanderson, Committee Vice-chair
9:05 a.m.	P&T/DUR process overview	Donna Sullivan, HCA
9:20 a.m.	Therapeutic class review: <ul style="list-style-type: none">• Anticonvulsants• Anxiolytics<ul style="list-style-type: none">○ Stakeholder input○ Motion• Cephalosporins and related antibiotics• Fluoroquinolones- oral• Lincosamides/Oxazolidinones/Streptogramins• Tetracyclines• Antifungals- oral• Antifungals- topical• Antivirals- oral• Hepatitis B agents• Immunosuppressives, oral<ul style="list-style-type: none">○ Stakeholder input*○ Motion	Stephanie Christofferson, Magellan
10:20 a.m.	Break	All
10:35 a.m.	Therapeutic class review: <ul style="list-style-type: none">• Analgesics, narcotics short<ul style="list-style-type: none">○ Stakeholder input*○ Motion• Lipotropics, other• Antihypertensives, sympatholytics• Sinus node inhibitors• Vasodilators, coronary<ul style="list-style-type: none">○ Stakeholder input*○ Motion• Bone resorption suppression and related agents• Thyroid hormones• BPH treatments• Contraceptives, other• H. Pylori treatment• Phosphate binders• Methotrexate	Stephanie Christofferson, Magellan

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions
please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	
11:40 a.m.	Lunch	All
12:40 p.m.	Clinical review: <ul style="list-style-type: none"> ● Antihyperuricemics ● BPH Treatments ● Enzyme Replacement, Gaucher's Disease ● GI Motility, Chronic ● HAE Treatments ● Immunomodulators, Asthma ● Movement Disorders <ul style="list-style-type: none"> ○ Stakeholder input* 	April Phillips, HCA
2:30 p.m.	Drug Utilization Review Board Adjourns	Dale Sanderson, Committee Vice-chair

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.